This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rowinsky, E. K. Articles by Donehower, R. C. Search for Related Content PubMed PubMed Citation Articles by Rowinsky, E. K. Articles by Donehower, R. C.

Phase I and Pharmacological Study of the Novel Topoisomerase I Inhibitor 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) Administered as a Ninety-Minute Infusion Every 3 Weeks¹

The Johns Hopkins Oncology Center, Baltimore, Maryland 21287-8934 [E. K. R., L. B. G., D. S. E., S. E. S., B. G. L., T-L. C., R. C. D.],, and G. H. Besselaar Associates, Princeton, New Jersey 08543 [M. R.]

² To whom requests for reprints should be addressed, at The Johns Hopkins Oncology Center, Division of Pharmacology and Experimental Therapeutics, 1-121, 600 North Wolfe Street, Baltimore, MD 21287-8934.

7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11; Irinotecan), a semisynthetic analogue of camptothecin (CPT) with broad preclinical antitumor activity, has demonstrated impressive activity in phase II trials in Japan in advanced small and non-small cell lung, colorectal, cervical, and ovarian carcinomas, as well as in refractory lymphomas and leukemias. In this phase I and pharmacological study, 90-min infusions of CPT-11 were administered every 3 weeks at doses ranging from 100 to 345 mg/m² to patients with solid malignancies. Acute, severe, and refractory vomiting, diarrhea, and/or abdominal cramps associated with flushing, warmth, and diaphoresis occurred in the immediate posttreatment period at the 240-mg/m² dose level in several patients who were not treated with premedications. The characteristics and temporal nature of these toxicities, the prompt resolution of symptoms following treatment with diphenhydramine, and the successful use of a premedication regimen consisting of ondansetron and diphenhydramine in preventing these acute effects suggest that vasoactive substances are involved in the mediation of these acute toxicities. With the routine use of these premedications, there was no single toxicity type that limited the escalation of CPT-11 doses. Instead, a constellation of severe hematological and gastrointestinal effects precluded the repetitive administration of CPT-11 at doses above 240 mg/m², the maximum tolerated dose and recommended phase II dose on this Schedule. Major responses were observed in patients with advanced colorectal, cervical, and renal cancers. The disposition of total CPT-11 in plasma was fit by a biexponential kinetic model with renal elimination accounting for 37 ± 4% (SE) of total drug disposition. The C_max for the active metabolite of CPT-11, 7-ethyl-10-hydroxycamptothecin (SN-38), was achieved at 2.2 ± 0.1 h after treatment, and mean residence times for both CPT-11 and SN-38 were long, 9.1 and 10.0 h, respectively. Compared with topotecan, another CPT analogue under development, a larger proportion of total drug exposure was accounted for by the active lactone (closed-ring) forms of CPT-11 and SN-38; areas under the time-versus concentration curve for their respective lactone were 44 and 50% of areas under the time-versus concentration curve for total CPT-11 and SN-38. Although intermittent dosing schedules appear to be superior to single dosing schedules for CPT and some CPT analogues in preclinical tumor models, the maintenance of biologically relevant concentrations of SN-38 for relatively long durations may negate the potential pharmacological benefits of intermittent and continuous administration schedules for CPT-11. The clinical activity observed with CPT-11 on the single dosing schedule and the lack of severe diarrhea after repetitive dosing at the maximum tolerated dose, which has been problematic on intermittent schedules, suggest that the single dosing schedule should be evaluated further in the phase II setting and in the development of combination chemotherapy regimens, particularly those containing both CPT-11 and 5-fluorouracil in which diarrhea is a significant concern.

¹ Supported by a grant from Yakult Honsha Company, Tokyo, Japan, and Daiichi Pharmaceutical Company, Tokyo, Japan. Presented in part at the annual meeting of the American Society of Clinical Oncology, San Diego, CA, May 17–19, 1992.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/27/93. Accepted 11/15/93.

This article has been cited by other articles:

				J. Homsi, G. R. Simon, C. R. Garrett, G. Springett, R. De Conti, A. A. Chiappori, P. N. Munster, M. K. Burton, S. Stromatt, C. Allievi, et al. Phase I Trial of Poly-L-Glutamate Camptothecin (CT-2106) Administered Weekly in Patients with Advanced Solid Malignancies Clin. Cancer Res., October 1, 2007; 13(19): 5855 - 5861. [Abstract] [Full Text] [PDF]

				J. Yang, D. Shi, D. Yang, X. Song, and B. Yan Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2 Mol. Pharmacol., September 1, 2007; 72(3): 686 - 694. [Abstract] [Full Text] [PDF]

				W. L. Furman, K. R. Crews, C. Billups, J. Wu, A. J. Gajjar, N. C. Daw, C. C. Patrick, C. Rodriguez-Galindo, C. F. Stewart, J. S. Dome, et al. Cefixime Allows Greater Dose Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., February 1, 2006; 24(4): 563 - 570. [Abstract] [Full Text] [PDF]

				M. Michael, M. Brittain, J. Nagai, R. Feld, D. Hedley, A. Oza, L. Siu, and M. J. Moore Phase II Study of Activated Charcoal to Prevent Irinotecan-Induced Diarrhea J. Clin. Oncol., November 1, 2004; 22(21): 4410 - 4417. [Abstract] [Full Text] [PDF]

				E. Rouits, M. Boisdron-Celle, A. Dumont, O. Guerin, A. Morel, and E. Gamelin Relevance of Different UGT1A1 Polymorphisms in Irinotecan-Induced Toxicity: A Molecular and Clinical Study of 75 Patients Clin. Cancer Res., August 1, 2004; 10(15): 5151 - 5159. [Abstract] [Full Text] [PDF]

				E. A. Perez, D. W. Hillman, J. A. Mailliard, J. N. Ingle, J. M. Ryan, T. R. Fitch, K. M. Rowland, C. G. Kardinal, J. E. Krook, J. W. Kugler, et al. Randomized Phase II Study of Two Irinotecan Schedules for Patients With Metastatic Breast Cancer Refractory to an Anthracycline, a Taxane, or Both J. Clin. Oncol., July 15, 2004; 22(14): 2849 - 2855. [Abstract] [Full Text] [PDF]

				L. M. Wagner, K. R. Crews, L. C. Iacono, P. J. Houghton, C. E. Fuller, M. B. McCarville, R. E. Goldsby, K. Albritton, C. F. Stewart, and V. M. Santana Phase I Trial of Temozolomide and Protracted Irinotecan in Pediatric Patients with Refractory Solid Tumors Clin. Cancer Res., February 1, 2004; 10(3): 840 - 848. [Abstract] [Full Text] [PDF]

				N. Mizuno, T. Niwa, Y. Yotsumoto, and Y. Sugiyama Impact of Drug Transporter Studies on Drug Discovery and Development Pharmacol. Rev., September 1, 2003; 55(3): 425 - 461. [Abstract] [Full Text] [PDF]

				M. A. Garrison, L. A. Hammond, C. E. Geyer Jr., G. Schwartz, A. W. Tolcher, L. Smetzer, J. A. Figueroa, M. Ducharme, J. Coyle, C. H. Takimoto, et al. A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies Clin. Cancer Res., July 1, 2003; 9(7): 2527 - 2537. [Abstract] [Full Text] [PDF]

				E. Raymond, M. Fabbro, V. Boige, O. Rixe, M. Frenay, G. Vassal, S. Faivre, E. Sicard, C. Germa, J. M. Rodier, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma Ann. Onc., April 1, 2003; 14(4): 603 - 614. [Abstract] [Full Text] [PDF]

				R. Xie, R. H.J. Mathijssen, A. Sparreboom, J. Verweij, and M. O. Karlsson Clinical Pharmacokinetics of Irinotecan and Its Metabolites: A Population Analysis J. Clin. Oncol., August 1, 2002; 20(15): 3293 - 3301. [Abstract] [Full Text] [PDF]

				G. Xu, W. Zhang, M. K. Ma, and H. L. McLeod Human Carboxylesterase 2 Is Commonly Expressed in Tumor Tissue and Is Correlated with Activation of Irinotecan Clin. Cancer Res., August 1, 2002; 8(8): 2605 - 2611. [Abstract] [Full Text] [PDF]

				H. Minami, H. Fujii, T. Igarashi, K. Itoh, K. Tamanoi, T. Oguma, and Y. Sasaki Phase I and Pharmacological Study of a New Camptothecin Derivative, Exatecan Mesylate (DX-8951f), Infused Over 30 Minutes Every Three Weeks Clin. Cancer Res., October 1, 2001; 7(10): 3056 - 3064. [Abstract] [Full Text] [PDF]

				R. H. J. Mathijssen, R. J. van Alphen, J. Verweij, W. J. Loos, K. Nooter, G. Stoter, and A. Sparreboom Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11) Clin. Cancer Res., August 1, 2001; 7(8): 2182 - 2194. [Abstract] [Full Text] [PDF]

				U. Vanhoefer, A. Harstrick, W. Achterrath, S. Cao, S. Seeber, and Y. M. Rustum Irinotecan in the Treatment of Colorectal Cancer: Clinical Overview J. Clin. Oncol., March 1, 2001; 19(5): 1501 - 1518. [Abstract] [Full Text] [PDF]

				V. Boige, E. Raymond, S. Faivre, M. Gatineau, K. Meely, S. Mekhaldi, P. Pautier, M. Ducreux, O. Rixe, and J.-P. Armand Phase I and Pharmacokinetic Study of the Camptothecin Analog DX-8951f Administered as a 30-Minute Infusion Every 3 Weeks in Patients With Advanced Cancer J. Clin. Oncol., December 1, 2000; 18(23): 3986 - 3992. [Abstract] [Full Text] [PDF]

				E. K. Rowinsky, T. R. Johnson, C. E. Geyer Jr, L. A. Hammond, S. G. Eckhardt, R. Drengler, L. Smetzer, J. Coyle, J. Rizzo, G. Schwartz, et al. DX-8951f, a Hexacyclic Camptothecin Analog, on a Daily-Times-Five Schedule: A Phase I and Pharmacokinetic Study in Patients With Advanced Solid Malignancies J. Clin. Oncol., September 17, 2000; 18(17): 3151 - 3163. [Abstract] [Full Text] [PDF]

				H. C. Pitot, R. M. Goldberg, J. M. Reid, J. A. Sloan, P. A. Skaff, C. Erlichman, J. Rubin, P. A. Burch, A. A. Adjei, S. A. Alberts, et al. Phase I Dose-finding and Pharmacokinetic Trial of Irinotecan Hydrochloride (CPT-11) Using a Once-Every-Three-Week Dosing Schedule for Patients with Advanced Solid Tumor Malignancy Clin. Cancer Res., June 1, 2000; 6(6): 2236 - 2244. [Abstract] [Full Text]

				M. K. Ma, W. C. Zamboni, K. M. Radomski, W. L. Furman, V. M. Santana, P. J. Houghton, S. K. Hanna, A. K. Smith, and C. F. Stewart Pharmacokinetics of Irinotecan and Its Metabolites SN-38 and APC in Children with Recurrent Solid Tumors after Protracted Low-Dose Irinotecan Clin. Cancer Res., March 1, 2000; 6(3): 813 - 819. [Abstract] [Full Text]

				C. H. Takimoto, G. Morrison, N. Harold, M. Quinn, B. P. Monahan, R. A. Band, J. Cottrell, A. Guemei, V. Llorens, H. Hehman, et al. Phase I and Pharmacologic Study of Irinotecan Administered as a 96-Hour Infusion Weekly to Adult Cancer Patients J. Clin. Oncol., February 1, 2000; 18(3): 659 - 659. [Abstract] [Full Text] [PDF]

				C. Lhomme, P. Fumoleau, P. Fargeot, Y. Krakowski, V. Dieras, J. Chauvergne, P. Vennin, P. Rebattu, H. Roche, J.-L. Misset, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix J. Clin. Oncol., October 1, 1999; 17(10): 3136 - 3142. [Abstract] [Full Text] [PDF]

				R. F. DeVore, D. H. Johnson, J. Crawford, J. Garst, I. W. Dimery, J. Eckardt, S. G. Eckhardt, G. L. Elfring, L. J. Schaaf, C. K. Hanover, et al. Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., September 1, 1999; 17(9): 2710 - 2710. [Abstract] [Full Text] [PDF]

				W. L. Furman, C. F. Stewart, C. A. Poquette, C. B. Pratt, V. M. Santana, W. C. Zamboni, L. C. Bowman, M. K. Ma, F. A. Hoffer, W. H. Meyer, et al. Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children J. Clin. Oncol., June 1, 1999; 17(6): 1815 - 1815. [Abstract] [Full Text] [PDF]

				V. M.M. Herben, J. H.M. Schellens, M. Swart, G. Gruia, L. Vernillet, J. H. Beijnen, and W. W. ten Bokkel Huinink Phase I and Pharmacokinetic Study of Irinotecan Administered as a Low-Dose, Continuous Intravenous Infusion Over 14 Days in Patients With Malignant Solid Tumors J. Clin. Oncol., June 1, 1999; 17(6): 1897 - 1897. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, Y. Shimada, K. Shirao, S. Seki, H. Saito, Y. Sakata, and I. Hyodo Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer J. Clin. Oncol., January 1, 1999; 17(1): 319 - 319. [Abstract] [Full Text] [PDF]

				J. A. Skirvin and V. Relias Review : Topoisomerase I inhibitors: 2. Irinotecan Journal of Oncology Pharmacy Practice, June 1, 1998; 4(2): 103 - 116. [Abstract] [PDF]

				L. B. Saltz Clinical Use of Irinotecan:Current Status and Future Considerations Oncologist, December 1, 1997; 2(6): 402 - 409. [Abstract] [Full Text] [PDF]

				X.-Y. Chu, Y. Kato, K. Niinuma, K.-I. Sudo, H. Hakusui, and Y. Sugiyama Multispecific Organic Anion Transporter Is Responsible for the Biliary Excretion of the Camptothecin Derivative Irinotecan and its Metabolites in Rats J. Pharmacol. Exp. Ther., April 1, 1997; 281(1): 304 - 314. [Abstract] [Full Text]